
    
      Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance
      informed 2nd-line ARV implementation study.

      DURATION

      Up to 3 years

      SAMPLE SIZE

      150

      POPULATION

      HIV-2-infected adults (â‰¥18 years old); ARV-experienced, with virologic failure on 1st-line
      2NRTI+LPV/r in the ISAARV program.

      STRATIFICATION

      By ARV resistance

      REGIMEN OR INTERVENTION

      Intervention: Implement real time ARV resistance testing using rapid DBS/CS ARV Regimens:
      Based on ARV resistance testing

        1. No resistance: Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF
           300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg
           BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) +Enhanced Adherence Counseling

        2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg
           QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC +
           LPV/r + RAL) + Enhanced Adherence Counseling

        3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD
           + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID + Raltegravir 400mg
           BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
    
  